This article is more than 5 years old. Information may no longer be current.

Yutiq reduces recurrence of posterior segment uveitis

Issue: September 10, 2019

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Quan Dong Nguyen

CHICAGO — Treatment with a single intravitreal injection of Yutiq can significantly reduce recurrence rates of noninfectious uveitis affecting the posterior segment, according to a speaker here.

“Patients with uveitis of the posterior segment who receive one fluocinolone acetonide implant throughout a 36-month period are more likely to achieve and maintain inflammation control. They are less likely for the need of systemic or local rescue therapy, and have a better chance of resolution of macular edema,” Quan Dong Nguyen, MD, MSc, said at the American Society of Retina Specialists annual meeting.

The controlled, prospective, double-masked, multicenter trial randomized 87 patients with recurrent noninfectious posterior segment uveitis to receive a 0.18 mg fluocinolone acetonide insert (Yutiq, EyePoint Pharmaceuticals) and 42 patients to receive sham treatment.

At 36 months, 42% of treated subjects required IOP lowering medications compared with 33% of sham participants. However, 85% of treated participants with macular edema at baseline experienced resolution compared with 70% of sham participants, Nguyen said.

“Over a 36-month period there was an overall gain of 9.1 letters for those who received the fluocinolone implant compared to 2.5 letters for those randomized to the sham group,” Nguyen said.

IOP lowering surgeries were required in 5.7% of treated participants compared with 11.9% of sham participants. Additionally, 73.8% of treated participants required cataract surgery compared with 23.8% of sham participants. – by Robert Linnehan

Reference:

Nguyen QD. 36-Month outcomes of injectable fluocinolone acetonide intravitreal insert on recurrences of non-infectious posterior segment uveitis. Presented at: American Society of Retina Specialists annual meeting; July 27-30, 2019; Chicago.

Disclosure: Nguyen reports he is an advisor for EyePoint Pharmaceuticals.